What is it about?

In severe COVID-19 pneumonia, an excessive inflammatory response is the main cause of death, and corticosteroids save lives. Guidelines recommend dexamethasone 6 mg daily for 7-10 days, but it was unclear whether higher doses for longer could do better. In the MEDEAS randomised trial, conducted in several Italian hospitals, 677 adults with COVID-19 pneumonia needing oxygen or non-invasive ventilation received either methylprednisolone 80 mg as a continuous infusion for 8 days followed by slow tapering, or standard dexamethasone. At 28 days, death rates were similar (10.4% vs 12.1%), as were need for mechanical ventilation, intensive care admission and tracheostomy. Methylprednisolone lowered inflammation markers more but led to a slightly longer hospital stay.

Featured Image

Why is it important?

This large randomised trial shows that prolonged, higher-dose methylprednisolone offers no major advantage over the simpler standard dexamethasone regimen. It supports current guidelines and the idea that the benefit of corticosteroids in COVID-19 pneumonia is a class effect of low-dose treatment, avoiding unnecessary exposure to higher steroid doses.

Perspectives

During the pandemic we learned that rigorous trials are the only way to separate hope from evidence. I am glad our centre in Trieste contributed to MEDEAS: a negative result is still a valuable result, because it protects patients from more aggressive treatments that do not add benefit.

Professor Stefano Di Bella
Universita degli Studi di Trieste

Read the Original

This page is a summary of: Prolonged higher dose methylprednisoloneversusconventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS), European Respiratory Journal, November 2022, European Respiratory Society (ERS),
DOI: 10.1183/13993003.01514-2022.
You can read the full text:

Read

Contributors

The following have contributed to this page